METHOD FOR TREATING EROSIVE FORM OF GASTROESOPHAGEAL REFLUX DISEASE IN PATIENTS PUT ON CHEMOTHERAPY Russian patent published in 2018 - IPC A61K31/4439 A61K31/575 A61P1/04 

FIELD: medicine.

SUBSTANCE: invention relates to medicine and can be used to treat the erosive form of gastroesophageal reflux disease in patients put on chemotherapy. For this purpose, omeprazole is prescribed to patients at a dose of 20 mg twice a day for 7 days. In determining the refractivity of the erosive form of gastroesophageal reflux disease by the 7 day treatment of omeprazole, which consists in the absence of a decrease in the overall intensity of clinical symptoms by less than 50 % according to the visual analogue scale, prescribe omeprazole in a doubled dose. When verifying the refractivity of the erosive form of gastroesophageal reflux disease to 7 day treatment with a double dose of omeprazole, which consists in the absence of a decrease in the overall intensity of clinical symptoms by less than 50 % in accordance with the visual analogue scale and the absence of positive dynamics of the endoscopic picture of the mucosa of the esophagus according to the data of fibro-esophagogastroduodenoscopy, additionally prescribe ursodeoxycholic acid at a dose of 250 mg 3 times a day. Conduct a control of the erosion of the esophagus mucosa by means of fibro-esophagogastroduodenoscopy every 2 weeks. When ascertaining the healing of erosions in the mucous membrane of the esophagus, the dose of omeprazole is reduced to 20 mg twice a day, while taking ursodeoxycholic acid 250 mg 3 times daily for the whole period of chemotherapy, but not less than 16–24 weeks.

EFFECT: invention makes it possible to reduce the risk of adverse outcomes (preservation of heartburn, pain, eructations) in the treatment of erosive forms of gastroesophageal reflux disease in patients put on chemotherapy.

1 cl, 1 ex